<DOC>
	<DOC>NCT02856477</DOC>
	<brief_summary>The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients. Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.</brief_summary>
	<brief_title>Pharmacogenetic and Antidepressant Treatment in Elderly</brief_title>
	<detailed_description />
	<criteria>current major depressive disorder antidepressant treatment dextromethorphan contraindication other psychiatric disorder kidney failure liver failure mini mental State Examination (MMSE)&lt;18</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>